Dr. Arend on Personalized Medicine for Endometrial Cancer

Rebecca C. Arend, MD
Published Online: Thursday, Jun 08, 2017



Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses personalized medicine for patients with endometrial cancer.

According to Arend, there has been a personalized medicine initiative that does panel sequencing on recurrent tumors. It is known that if a patient has a somatic BRCA mutation, they can receive rucaparib (Rubraca). Additionally, if a patient’s tumor is microsatellite instability-high (MSI-H), immunotherapy is available.

In the future, more research is needed to have more tumors looking like the MSI-H tumors, in order for them to respond to immunotherapy, states Arend.
 


Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses personalized medicine for patients with endometrial cancer.

According to Arend, there has been a personalized medicine initiative that does panel sequencing on recurrent tumors. It is known that if a patient has a somatic BRCA mutation, they can receive rucaparib (Rubraca). Additionally, if a patient’s tumor is microsatellite instability-high (MSI-H), immunotherapy is available.

In the future, more research is needed to have more tumors looking like the MSI-H tumors, in order for them to respond to immunotherapy, states Arend.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Precision Medicine: The Evolving Role of Genomics and Proteomics in Cancer Treatment: Current and Emerging Roles for Molecular Testing Technologies: Real-World Application into PracticeAug 29, 20171.5
Community Practice Connections™: Oncogenic Tumor Board in NSCLC: Targeting Driver Mutations to Maximize Therapeutic OutcomesAug 31, 20171.5
Publication Bottom Border
Border Publication
$emailPop$